Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel
NCT ID: NCT01510015
Last Updated: 2012-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2012-01-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Episode Schizophrenia and Cannabis-Related Disorder Study
NCT00573287
D-Serine Monotherapy for Schizophrenia
NCT00215917
Safety and Efficacy of Seroquel in First Episode Schizophrenia
NCT00254241
One Year Drug Treatment in First-Episode Schizophrenia
NCT00159081
Risperidone Treatment in Dually-Diagnosed Individuals - 2
NCT00000267
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-psychotic medication
Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
Risperidone
variable dose
Counseling
Participants will receive individual and group therapy
Risperidone
variable dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risperidone
variable dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* under 18
* neurological damage
* HIV positive
* dependence on other drugs such as heroin
* cocaine or alcohol
21 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michal Roll PhD,MBA
Head of Research and Development
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michal Roll, Ph.D
Role: STUDY_DIRECTOR
Sourasky Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sourasky Medical center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0503-11-TLV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.